Penetrium Bioscience Inc. (KOSDAQ:187660)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Clinical Business Agency	9.29B	13.49B	-	-	-
Clinical Business Agency Growth	-31.11%	-	-	-	-
Rental Business	429.83M	266.71M	-	-	-
Rental Business Growth	61.16%	-	-	-	-
Other Business	23.10M	34.62M	-	-	-
Other Business Growth	-33.28%	-	-	-	-
Biotechnology	-	-	14.88B	13.98B	13.12B
Biotechnology Growth	-	-	6.47%	6.54%	28.55%
Total	9.74B	13.79B	14.88B	13.98B	13.12B
Total Growth	-29.33%	-7.34%	6.47%	6.54%	28.55%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
South Korea	9.74B	13.79B	14.88B	13.98B	13.12B
South Korea Growth	-29.33%	-7.34%	6.47%	6.54%	28.55%
Total	9.74B	13.79B	14.88B	13.98B	13.12B
Total Growth	-29.33%	-7.34%	6.47%	6.54%	28.55%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2024

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 29, 2026

Data Sources Report a data error